Press coverage about Iradimed (NASDAQ:IRMD) has been trending positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a news impact score of 0.28 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.4319680893128 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Head to Head Review: Iradimed (IRMD) vs. Its Competitors (americanbankingnews.com)
- Iradimed (IRMD) Now Covered by Analysts at Roth Capital (americanbankingnews.com)
- Critical Survey: Iradimed (IRMD) vs. Its Peers (americanbankingnews.com)
- Edited Transcript of IRMD earnings conference call or presentation 6-Feb-18 4:00pm GMT (finance.yahoo.com)
- Iradimed Corp (IRMD) Given Consensus Recommendation of “Strong Buy” by Brokerages (americanbankingnews.com)
Separately, Zacks Investment Research raised shares of Iradimed from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $17.33.
Iradimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 6th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.04. Iradimed had a return on equity of 3.03% and a net margin of 2.17%. The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.72 million. During the same quarter in the previous year, the business earned $0.11 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. sell-side analysts forecast that Iradimed will post 0.25 earnings per share for the current year.
In other Iradimed news, insider Louis S. Waldman sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $13.83, for a total value of $414,900.00. Following the completion of the transaction, the insider now owns 5,221 shares in the company, valued at approximately $72,206.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 60.10% of the stock is owned by corporate insiders.
Iradimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.